---
title: Mycology
order: 3
category: Microbiology
status: complete
last_updated: '2025-01-09'
---

# Mycology

## Overview

Mycology is the study of fungi, eukaryotic organisms that exist as yeasts (unicellular) or molds (multicellular filamentous). Fungi are ubiquitous in nature and generally exist as saprophytes in the environment. While most fungi are harmless, some are pathogenic to humans, particularly in immunocompromised individuals. Fungal infections (mycoses) range from superficial skin and nail infections to life-threatening systemic diseases.

Fungi possess unique structural features including ergosterol in cell membranes (target for antifungals) and chitin in cell walls. They reproduce through spores and can exist in dimorphic forms (mold in environment, yeast in host tissue at 37°C). Understanding fungal biology, pathogenesis, and treatment is increasingly important due to rising rates of invasive fungal infections in immunocompromised populations.

### Key Characteristics

**Fungal Properties**:
- Eukaryotic organisms with membrane-bound organelles
- Cell wall contains chitin and β-glucan
- Cell membrane contains ergosterol (not cholesterol)
- Reproduce sexually and/or asexually via spores
- Obligate or facultative aerobes

**Morphological Forms**:
- **Yeasts**: Unicellular, round to oval, reproduce by budding
- **Molds**: Multicellular, filamentous hyphae forming mycelium
- **Dimorphic**: Mold at 25°C (environment), yeast at 37°C (body temperature)
- **Pseudohyphae**: Elongated yeast cells that remain attached

## Classification and Structure

### Classification by Morphology

**Yeasts**:
- Unicellular fungi
- Reproduce by budding
- Examples: Candida, Cryptococcus, Malassezia

**Molds**:
- Multicellular with hyphae (branching filaments)
- **Septate hyphae**: With cross-walls (Aspergillus, dermatophytes)
- **Nonseptate hyphae**: Without cross-walls/coenocytic (Mucor, Rhizopus)
- Reproduce via spores (conidia)

**Dimorphic Fungi**:
- Mold form in environment (25°C)
- Yeast form in tissue (37°C)
- Examples: Histoplasma, Blastomyces, Coccidioides, Sporothrix

### Fungal Structure

**Cell Wall**:
- Outer layer: Mannoproteins
- Inner layer: β-1,3-glucan and chitin
- Provides rigidity and shape
- Target for echinocandin antifungals

**Cell Membrane**:
- Phospholipid bilayer with ergosterol
- Ergosterol unique to fungi (target for azoles and polyenes)
- Sterol synthesis pathway differs from mammalian cholesterol

**Reproductive Structures**:
- **Sexual spores**: Zygospores, ascospores, basidiospores
- **Asexual spores**: Conidia, sporangiospores
- **Budding**: Yeast reproduction (Candida, Cryptococcus)

### Classification by Infection Site

**Superficial Mycoses**:
- Limited to outer layers of skin and hair
- Minimal inflammation
- Examples: Pityriasis versicolor, tinea nigra

**Cutaneous Mycoses**:
- Involve keratinized tissues (skin, hair, nails)
- Dermatophytes (ringworm)
- Examples: Tinea corporis, tinea pedis, tinea capitis

**Subcutaneous Mycoses**:
- Involve dermis and subcutaneous tissue
- Usually traumatic inoculation
- Examples: Sporotrichosis, chromoblastomycosis, mycetoma

**Systemic Mycoses**:
- Involve internal organs, often disseminated
- **Endemic**: Specific geographic regions
- **Opportunistic**: Immunocompromised hosts

## Pathophysiology

### Host Defense Mechanisms

**Innate Immunity**:
- Physical barriers (intact skin, mucosa)
- Neutrophils (primary defense against yeasts and molds)
- Macrophages (phagocytosis and killing)
- Complement activation
- Pattern recognition receptors (dectin-1 for β-glucan)

**Adaptive Immunity**:
- Th1 response (cell-mediated immunity) for intracellular fungi
- Th17 response for mucosal candidiasis
- Antibody production (limited protective role)

**Risk Factors for Fungal Infections**:
- Neutropenia (chemotherapy, bone marrow transplant)
- Cell-mediated immune defects (HIV/AIDS, corticosteroids)
- Disrupted barriers (burns, catheters, surgery)
- Broad-spectrum antibiotics (Candida overgrowth)
- Diabetes mellitus
- Prematurity
- Environmental exposure

### Fungal Virulence Factors

**Adherence**:
- Adhesins bind to host epithelial cells
- Biofilm formation (Candida on medical devices)

**Invasion**:
- Proteases and phospholipases degrade tissue
- Morphological switching (yeast to hyphal forms in Candida)

**Immune Evasion**:
- Capsule prevents phagocytosis (Cryptococcus)
- Melanin production (Cryptococcus)
- Intracellular survival in macrophages (Histoplasma)
- Antigenic variation

**Toxins and Enzymes**:
- Gliotoxin (immunosuppressive - Aspergillus)
- Hemolysins
- Proteases

## Clinical Presentation

### Superficial and Cutaneous Mycoses

**Dermatophytoses (Tinea)**:

Caused by dermatophytes (Trichophyton, Microsporum, Epidermophyton):
- Infect keratinized tissues (skin, hair, nails)
- Transmitted person-to-person, animal-to-person, or via fomites

**Tinea Corporis** (body ringworm):
- Circular erythematous patches with central clearing
- Raised, scaly border
- Pruritic

**Tinea Cruris** (jock itch):
- Groin and inner thigh involvement
- Spares scrotum
- More common in males

**Tinea Pedis** (athlete's foot):
- Interdigital scaling, maceration
- Moccasin distribution
- Most common dermatophytosis

**Tinea Capitis** (scalp ringworm):
- Scalp scaling, alopecia, kerion (boggy mass)
- Common in children
- May cause permanent hair loss

**Tinea Unguium** (onychomycosis):
- Nail thickening, discoloration, subungual debris
- Difficult to treat, requires prolonged therapy

**Diagnosis**:
- KOH preparation shows hyphae
- Fungal culture on Sabouraud agar
- Wood's lamp (some Microsporum fluoresce)

**Treatment**:
- Topical azoles (clotrimazole, miconazole) for limited disease
- Oral terbinafine or itraconazole for extensive/nail involvement

**Malassezia furfur**:
- Lipophilic yeast, part of normal skin flora
- **Pityriasis versicolor**: Hypopigmented or hyperpigmented patches on trunk
- **Folliculitis**: Acneiform eruption
- KOH shows "spaghetti and meatballs" (hyphae and yeast)
- Treatment: Topical azoles, selenium sulfide shampoo

### Subcutaneous Mycoses

**Sporothrix schenckii** (Sporotrichosis):
- Dimorphic fungus
- **Transmission**: Traumatic inoculation (rose thorns, gardening)
- **Lymphocutaneous form**: Nodular lymphangitis ascending from inoculation site
- **Fixed cutaneous form**: Localized lesion
- **Diagnosis**: Culture, histopathology (cigar-shaped yeast)
- **Treatment**: Itraconazole (potassium iodide for cutaneous)

**Chromoblastomycosis**:
- Caused by dematiaceous (pigmented) fungi
- Traumatic inoculation
- Verrucous nodules, typically on lower extremities
- "Copper pennies" or sclerotic bodies on histology
- Treatment: Prolonged antifungal therapy, often refractory

**Mycetoma** (Madura foot):
- Chronic subcutaneous infection
- Triad: Tumefaction, draining sinuses, grains
- Eumycotic (fungal) vs actinomycotic (bacterial)
- Treatment: Prolonged therapy, often requires surgery

### Opportunistic Mycoses

**Candida species**:

Most common: C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. auris

**Mucocutaneous Candidiasis**:

1. **Oral Thrush**:
   - White plaques on tongue, buccal mucosa
   - Removable with scraping, leaving erythema
   - Risk factors: Antibiotics, corticosteroids, HIV, dentures
   - Treatment: Nystatin suspension, clotrimazole troches, fluconazole

2. **Esophageal Candidiasis**:
   - AIDS-defining illness (CD4 < 100)
   - Odynophagia, dysphagia, retrosternal pain
   - White plaques on endoscopy
   - Treatment: Fluconazole or echinocandin

3. **Vulvovaginal Candidiasis**:
   - Pruritus, thick white discharge ("cottage cheese")
   - Risk factors: Antibiotics, pregnancy, diabetes
   - Treatment: Topical azoles, oral fluconazole

4. **Cutaneous Candidiasis**:
   - Intertriginous areas (skin folds)
   - Satellite lesions
   - Diaper dermatitis in infants

5. **Chronic Mucocutaneous Candidiasis**:
   - Persistent Candida infections
   - Associated with T-cell defects
   - AIRE gene mutations

**Invasive Candidiasis**:

1. **Candidemia**:
   - Bloodstream infection
   - Risk factors: Central lines, TPN, broad-spectrum antibiotics, neutropenia
   - High mortality (30-40%)
   - Treatment: Echinocandin (caspofungin, micafungin) first-line

2. **Chronic Disseminated Candidiasis** (hepatosplenic):
   - Multiple abscesses in liver and spleen
   - Occurs in neutropenic patients (leukemia)
   - Persistent fever despite antibacterial therapy
   - Treatment: Prolonged azole or amphotericin B

3. **Candida Endocarditis**:
   - Prosthetic valves, IV drug users
   - Large vegetations
   - Treatment: Amphotericin B + flucytosine, usually requires valve replacement

**Aspergillus species**:

Most common: A. fumigatus, A. flavus, A. niger

**Allergic Bronchopulmonary Aspergillosis (ABPA)**:
- Hypersensitivity reaction
- Asthma, cystic fibrosis patients
- Eosinophilia, elevated IgE, fleeting infiltrates
- Central bronchiectasis
- Treatment: Corticosteroids, itraconazole

**Aspergilloma** (fungus ball):
- Colonization of pre-existing cavity (TB, sarcoidosis)
- Hemoptysis
- "Air crescent sign" on CT
- Treatment: Observation or surgical resection if symptomatic

**Invasive Aspergillosis**:
- Neutropenic patients, hematopoietic stem cell transplant
- **Pulmonary**: Fever, cough, hemoptysis unresponsive to antibiotics
- "Halo sign" (early), "air crescent sign" (late) on CT
- Angioinvasion → hemorrhagic infarction
- **Dissemination**: CNS (brain abscesses), sinuses
- **Diagnosis**: Galactomannan antigen, β-D-glucan, culture, histopathology (septate hyphae with acute angle branching)
- **Treatment**: Voriconazole (first-line), isavuconazole, amphotericin B lipid formulation

**Cryptococcus neoformans**:
- Encapsulated yeast
- Environmental exposure (pigeon droppings, soil)
- **Risk**: HIV/AIDS (CD4 < 100), transplant recipients, chronic steroids

**Cryptococcal Meningitis**:
- Subacute onset: Headache, fever, altered mental status
- Often minimal meningeal signs
- **Diagnosis**:
  - CSF: High opening pressure, lymphocytic pleocytosis, low glucose
  - India ink stain (encapsulated yeast)
  - Cryptococcal antigen (serum and CSF) - highly sensitive
  - Culture
- **Treatment**:
  - Induction: Amphotericin B + flucytosine
  - Consolidation: Fluconazole
  - Maintenance: Fluconazole (until CD4 > 200 in HIV patients)
  - Serial lumbar punctures to manage elevated ICP

**Pulmonary Cryptococcosis**:
- Asymptomatic to severe pneumonia
- May disseminate to CNS

**Pneumocystis jirovecii**:
- Formerly classified as protozoan, now considered fungus
- Obligate extracellular organism

**Pneumocystis Pneumonia (PCP)**:
- AIDS-defining illness (CD4 < 200)
- **Presentation**: Subacute dyspnea, dry cough, fever
- **Physical exam**: Often unremarkable
- **Imaging**: Bilateral interstitial infiltrates, ground-glass opacities
- **Labs**: Elevated LDH, hypoxemia with increased A-a gradient
- **Diagnosis**:
  - BAL with methenamine silver or immunofluorescence stain
  - Cannot be cultured
- **Treatment**:
  - TMP-SMX (first-line)
  - Adjunctive corticosteroids if PaO2 < 70 mmHg
  - Alternatives: Pentamidine, atovaquone, clindamycin-primaquine
- **Prophylaxis**: TMP-SMX when CD4 < 200

**Mucormycosis** (Zygomycosis):
- Caused by Mucor, Rhizopus (nonseptate hyphae, wide-angle branching)
- **Risk factors**: Diabetic ketoacidosis, neutropenia, deferoxamine therapy, burns

**Rhinocerebral Mucormycosis**:
- Most common form
- Sinusitis → orbital invasion → intracranial extension
- Black necrotic eschar on palate or nasal turbinates
- Facial pain, proptosis, ophthalmoplegia
- Angioinvasion → thrombosis and infarction
- **Treatment**: Urgent surgical debridement + amphotericin B lipid formulation

**Pulmonary Mucormycosis**:
- Neutropenic patients
- Hemorrhagic pneumonia with infarction
- High mortality

### Endemic Mycoses

**Histoplasma capsulatum**:
- Dimorphic fungus
- **Endemic**: Mississippi and Ohio River valleys, Central/South America
- **Exposure**: Bird/bat droppings, soil, spelunking

**Acute Pulmonary Histoplasmosis**:
- Usually asymptomatic or flu-like illness
- Calcified granulomas, mediastinal lymphadenopathy

**Chronic Pulmonary Histoplasmosis**:
- COPD patients
- Cavitary lung disease mimicking tuberculosis

**Progressive Disseminated Histoplasmosis**:
- Immunocompromised (HIV with CD4 < 150)
- Fever, weight loss, hepatosplenomegaly, pancytopenia
- Adrenal insufficiency
- **Diagnosis**: Urine/serum Histoplasma antigen, culture, histopathology (macrophages with yeast)
- **Treatment**: Amphotericin B (severe) → itraconazole (mild-moderate)

**Coccidioides immitis/posadasii**:
- Dimorphic fungus
- **Endemic**: Southwestern US (Arizona, California - "Valley Fever"), Mexico, Central/South America
- **Exposure**: Dust inhalation (construction, earthquakes)

**Primary Pulmonary Coccidioidomycosis**:
- 60% asymptomatic
- Symptomatic: Flu-like illness, erythema nodosum, erythema multiforme
- Self-limited in most

**Disseminated Coccidioidomycosis**:
- <1% of infections
- Risk: Immunosuppression, pregnancy (3rd trimester), Filipino/African ancestry
- Meningitis, bone/joint, skin involvement
- **Diagnosis**: Serology (complement fixation, IgM/IgG), culture (biosafety level 3), histopathology (spherules with endospores)
- **Treatment**: Fluconazole or itraconazole (mild-moderate), amphotericin B (severe)

**Blastomyces dermatitidis**:
- Dimorphic fungus
- **Endemic**: Mississippi and Ohio River valleys, Great Lakes, southeastern US
- **Exposure**: Soil, decaying wood

**Pulmonary Blastomycosis**:
- Acute or chronic pneumonia
- Productive cough, fever, weight loss
- Can mimic TB or lung cancer

**Disseminated Blastomycosis**:
- Skin (verrucous lesions with central ulceration)
- Bone (osteomyelitis)
- Genitourinary
- **Diagnosis**: Culture, histopathology (broad-based budding yeast)
- **Treatment**: Itraconazole (mild-moderate), amphotericin B (severe)

**Paracoccidioides brasiliensis**:
- Dimorphic fungus
- **Endemic**: Latin America
- **Presentation**: Chronic pulmonary infection, mucosal ulcers ("mulberry" oral lesions)
- "Captain's wheel" or "steering wheel" appearance (multiple budding)
- Treatment: Itraconazole

## Diagnosis

### Microscopy

**KOH Preparation**:
- Direct examination of skin scrapings, nail clippings, hair
- Dissolves keratin, allows visualization of fungal elements
- Hyphae for dermatophytes, yeast for Candida

**Calcofluor White**:
- Fluorescent stain binds chitin and cellulose
- Enhanced visualization under UV microscopy

**Gram Stain**:
- Yeast visible (Candida, Cryptococcus)
- Not suitable for molds

**Special Stains**:
- **GMS (Gomori methenamine silver)**: All fungi (black)
- **PAS (Periodic acid-Schiff)**: Fungi and glycogen
- **Mucicarmine**: Cryptococcus capsule (red)
- **India ink**: Cryptococcus (negative staining of capsule)

### Culture

**Sabouraud Dextrose Agar**:
- Standard fungal culture medium
- Low pH inhibits bacterial growth
- Room temperature (25°C) for molds
- 37°C for dimorphic fungi (yeast phase)

**Growth Characteristics**:
- Slow growth (days to weeks)
- Colony morphology and pigmentation
- Microscopic morphology (spore types)

**Blood Culture**:
- BACTEC or BacT/ALERT systems detect Candida, Cryptococcus
- May be negative in disseminated endemic mycoses

### Antigen and Antibody Detection

**Cryptococcal Antigen**:
- Latex agglutination or lateral flow assay
- Serum and CSF
- High sensitivity and specificity

**Histoplasma Antigen**:
- Urine and serum
- Sensitive for disseminated disease

**Galactomannan**:
- Aspergillus antigen in serum and BAL
- Useful in neutropenic patients

**β-D-Glucan**:
- Cell wall component of most fungi (not Cryptococcus or Mucorales)
- Nonspecific but sensitive screening test

**Coccidioides Serology**:
- IgM (tube precipitin) - early infection
- IgG (complement fixation) - chronic infection, dissemination

### Molecular Methods

**PCR**:
- Rapid detection of fungal DNA
- Species identification
- Not widely standardized

**MALDI-TOF Mass Spectrometry**:
- Rapid identification from culture
- Protein fingerprinting

### Histopathology

**Tissue Biopsy**:
- Definitive diagnosis
- Special stains (GMS, PAS)
- Morphologic features guide identification

**Characteristic Findings**:
- **Candida**: Pseudohyphae and budding yeast
- **Aspergillus**: Septate hyphae, acute angle (45°) branching
- **Mucor**: Nonseptate hyphae, wide angle (90°) branching
- **Cryptococcus**: Encapsulated yeast, narrow-based budding
- **Histoplasma**: Small yeast within macrophages
- **Blastomyces**: Broad-based budding yeast
- **Coccidioides**: Spherules with endospores

## Treatment

### Antifungal Drug Classes

**Polyene Antifungals**:

**Amphotericin B**:
- **Mechanism**: Binds ergosterol, forms pores in cell membrane
- **Spectrum**: Broadest spectrum (most yeasts and molds)
- **Formulations**:
  - Conventional (deoxycholate) - highly nephrotoxic
  - Lipid formulations (liposomal, lipid complex) - less toxic
- **Uses**: Severe invasive infections, empiric antifungal therapy
- **Toxicity**: Nephrotoxicity, infusion reactions ("shake and bake"), hypokalemia, hypomagnesemia
- **Monitoring**: Electrolytes, renal function

**Nystatin**:
- Topical/oral use only (too toxic for IV)
- Oral thrush, cutaneous candidiasis

**Azole Antifungals**:

**Mechanism**: Inhibit ergosterol synthesis (14α-demethylase/CYP51A1)

**Imidazoles** (topical):
- Clotrimazole, miconazole, ketoconazole
- Dermatophytoses, cutaneous candidiasis

**Triazoles** (systemic):

1. **Fluconazole**:
   - Excellent oral bioavailability, CSF penetration
   - **Uses**: Candida (except C. krusei, many C. glabrata), Cryptococcus, Coccidioides
   - **Not active**: Aspergillus, Mucor
   - **Toxicity**: Generally well-tolerated, hepatotoxicity, QT prolongation

2. **Itraconazole**:
   - **Uses**: Dermatophytes, Blastomyces, Histoplasma, Sporothrix, Aspergillus
   - Requires acidic environment for absorption
   - **Toxicity**: Heart failure, hepatotoxicity
   - **Monitoring**: Drug levels, LFTs

3. **Voriconazole**:
   - **Uses**: Aspergillus (first-line), Candida, Scedosporium
   - Good CSF penetration
   - **Toxicity**: Visual disturbances, hepatotoxicity, photosensitivity, periostitis
   - **Monitoring**: Drug levels (wide variability due to CYP2C19 polymorphisms)

4. **Posaconazole**:
   - **Uses**: Aspergillus, Mucorales (only azole active), Fusarium
   - Prophylaxis in high-risk neutropenic patients
   - Extended-release tablet or IV formulation
   - **Monitoring**: Drug levels

5. **Isavuconazole**:
   - **Uses**: Aspergillus, Mucorales
   - Better tolerated than voriconazole (no visual side effects)

**Drug Interactions**: CYP450 inhibitors, multiple interactions

**Echinocandins**:

**Mechanism**: Inhibit β-1,3-glucan synthase (cell wall synthesis)

**Agents**: Caspofungin, micafungin, anidulafungin

**Spectrum**:
- **Active**: Candida (including azole-resistant), Aspergillus
- **Not active**: Cryptococcus (no β-glucan in capsule), Mucorales

**Uses**:
- First-line for candidemia and invasive candidiasis
- Salvage therapy for invasive aspergillosis

**Advantages**:
- Fungicidal against Candida
- Minimal toxicity
- Few drug interactions
- IV only (no oral formulation)

**Resistance**: Increasing in C. glabrata

**Antimetabolites**:

**Flucytosine (5-FC)**:
- **Mechanism**: Converted to 5-FU, inhibits DNA/RNA synthesis
- **Uses**: Combination with amphotericin B (Cryptococcus, Candida)
- **Toxicity**: Bone marrow suppression, hepatotoxicity
- **Monitoring**: Drug levels, CBC
- **Resistance**: Develops rapidly if used alone

**Allylamines**:

**Terbinafine**:
- **Mechanism**: Inhibits squalene epoxidase (ergosterol synthesis)
- **Uses**: Dermatophytes (onychomycosis)
- Oral therapy for nail infections
- Fungicidal

### Treatment by Infection Type

**Superficial/Cutaneous Mycoses**:
- Topical azoles (clotrimazole, miconazole, ketoconazole)
- Terbinafine cream
- Oral terbinafine or itraconazole for extensive disease or onychomycosis

**Mucocutaneous Candidiasis**:
- Oral thrush: Nystatin, clotrimazole troches, fluconazole
- Esophageal: Fluconazole or echinocandin
- Vulvovaginal: Topical azoles or oral fluconazole

**Invasive Candidiasis**:
- Echinocandin (first-line)
- Fluconazole (azole-susceptible species, stable patients)
- Amphotericin B (alternative)
- De-escalation based on species and susceptibility

**Invasive Aspergillosis**:
- Voriconazole (first-line)
- Isavuconazole
- Amphotericin B lipid formulation
- Combination therapy for severe cases

**Cryptococcal Meningitis**:
- Induction: Amphotericin B + flucytosine (2 weeks)
- Consolidation: Fluconazole (8 weeks)
- Maintenance: Fluconazole (until immune reconstitution)

**Mucormycosis**:
- Urgent surgical debridement
- Amphotericin B lipid formulation (high dose)
- Posaconazole or isavuconazole

**Endemic Mycoses**:
- **Mild-moderate**: Itraconazole or fluconazole
- **Severe/disseminated**: Amphotericin B → itraconazole

**PCP**:
- TMP-SMX (first-line)
- Adjunctive corticosteroids if severe

### Antifungal Resistance

**Mechanisms**:
- Altered drug target (azole resistance via ERG11 mutations)
- Overexpression of efflux pumps (azole resistance)
- Target overexpression
- Biofilm formation

**Emerging Resistant Organisms**:
- **Candida auris**: Multidrug-resistant, healthcare-associated
- **C. glabrata**: Echinocandin and azole resistance
- Azole-resistant Aspergillus (environmental triazole exposure)

**Susceptibility Testing**:
- Not routinely performed for all fungi
- Important for invasive infections and treatment failures
- Broth microdilution (CLSI/EUCAST standards)

## Prevention

### Infection Control

**Standard Precautions**:
- Hand hygiene
- Environmental cleaning

**Additional Measures**:
- HEPA filtration for immunocompromised patients
- Minimize dust exposure during construction
- Avoid exposure to high-risk environments (bird droppings, caves)

### Prophylaxis

**Primary Prophylaxis**:
- **PCP**: TMP-SMX for HIV patients with CD4 < 200
- **Candida**: Fluconazole in high-risk hematopoietic stem cell transplant
- **Aspergillus**: Posaconazole or voriconazole in high-risk neutropenic patients
- **Endemic fungi**: Itraconazole in highly endemic areas for very low CD4 counts

**Secondary Prophylaxis** (Maintenance):
- **Cryptococcus**: Fluconazole until immune reconstitution
- **Histoplasma**: Itraconazole until immune reconstitution
- **Coccidioides**: Fluconazole for disseminated disease

### Risk Reduction

**For Immunocompromised Patients**:
- Avoid gardening/soil exposure
- Avoid bird/bat habitats
- Avoid marijuana smoking (Aspergillus contamination)
- Neutropenic diet (avoid fresh flowers)

## Key Points

1. Fungi are eukaryotes with ergosterol-containing membranes and chitin cell walls
2. Dermatophytes cause superficial infections of keratinized tissues
3. Candida is the most common opportunistic fungal pathogen
4. Aspergillus causes invasive disease in neutropenic patients with angioinvasion
5. Cryptococcus causes meningitis in AIDS patients (CD4 < 100)
6. Mucormycosis occurs in diabetic ketoacidosis and requires surgical debridement
7. Endemic mycoses are geographically restricted dimorphic fungi
8. Pneumocystis pneumonia is an AIDS-defining illness requiring TMP-SMX
9. Amphotericin B has the broadest antifungal spectrum but significant toxicity
10. Azoles inhibit ergosterol synthesis and are used for many fungal infections
11. Echinocandins are first-line for invasive candidiasis
12. Antifungal resistance is an emerging problem, especially with C. auris

## References

1. Pappas PG, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.
2. Patterson TF, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60.
3. Perfect JR, et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291-322.
4. Wheat LJ, et al. Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807-25.
5. Murray PR, et al. Medical Microbiology. 9th ed. Elsevier; 2021.
6. Kauffman CA, et al. Clinical Mycology. 2nd ed. Oxford University Press; 2011.
